Evidence map›Paper›PMID 34931923›Full record

ArticleBioengineered2021

Bioinformatics and

Jingru Qin, Chao Guo, Lu Yang, Xiao Liang, Aijun Jiao, Keng Po Lai, Bin Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Therapeutic Potential of Biochanin A in Herpes Simplex Keratitis.Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jingru QinCollege of Pharmacy, Guangxi Medical University, Nanning, Guangxi, PR China.
Chao GuoDepartment of Pharmacy, Guigang City People's Hospital, the Eighth Affiliated Hospital of Guangxi Medical University, Guigang, Guangxi, PR China.
Lu YangLaboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Guilin, PR China.
Xiao LiangCollege of Pharmacy, Guangxi Medical University, Nanning, Guangxi, PR China.
Aijun JiaoCollege of Pharmacy, Guangxi Medical University, Nanning, Guangxi, PR China.
Keng Po LaiLaboratory of Environmental Pollution and Integrative Omics, Guilin Medical University, Guilin, PR China.ORCID 0000-0001-8237-6658
Bin YangCollege of Pharmacy, Guangxi Medical University, Nanning, Guangxi, PR China.
Guangxi Medical University · CNGuilin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe mortality due to the COVID-19 pandemic resulted from the lack of effective treatment. Although COVID-19 vaccines are available, their side effects have become a challenge for clinical use in patients with chronic diseases, especially cancer patients. In the current report, we applied network pharmacology and systematic bioinformatics to explore the use of biochanin A in patients with colorectal cancer (CRC) and COVID-19 infection. Using the network pharmacology approach, we identified two clusters of genes involved in immune response (

Indexed as

COVID-19 Drug TreatmentAnticarcinogenic AgentsAntiviral AgentsAtlases as TopicColorectal NeoplasmsCOVID-19Cyclin D1ErbB ReceptorsGene Expression Regulation, NeoplasticGenisteinHumansInterleukin-1alphaInterleukin-2Janus KinasesMetabolic Networks and PathwaysMolecular Targeted TherapyAnticarcinogenic AgentsAntiviral Agentsbiochanin ACCND1 protein, humanCyclin D1EGFR protein, humanErbB ReceptorsGenisteinIL1A protein, humanIL2 protein, humanIL6R protein, humanInterleukin-1alphaInterleukin-2Janus KinasesPhosphatidylinositol 3-KinasesPhytoestrogensPPAR gammaPPARG protein, humanProto-Oncogene Proteins c-aktReceptors, Interleukin-6STAT Transcription Factorsbiochanin abioinformaticsbiological functionColorectal cancerCOVID-19pharmaceutical target

Identifiers

PMID34931923
PMCPMC8809988
OpenAlexW4200216951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.